Upregulation of Indoleamine 2,3-dioxygenase 1 in tumor cells and tertiary lymphoid structures is a hallmark of inflamed non-small cell lung cancer.
Alban BessedeFlorent PeyraudSylvestre Le MoulecSophie CousinMathilde CabartFrançois ChomyChristophe ReyOren LaraOphélie OdinImane NafiaJean-Philippe GuéganAntoine ItalianoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
IDO1 pathway in NSCLC is driven by the immune system rather than by tumor cells. Targeting IDO1 in combination with anti-PD1/PDL1 might be beneficial only in patients with inflamed tumors and particularly in those bearing TLS.